Relmada Therapeutics Inc (RLMD) showcases robust clinical data and strategic financial moves, despite facing increased expenses and net loss.

Shift Up Q1 2026 Earnings and Future Strategy (以上引用) ■ Summary of Shift Up Q1 2026 Earnings and Status ▣ Q1 2026 Earnings ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the grant of a major ...

Tokyo’s defense exports are becoming tools for building a new middle power security network across the Indo-Pacific.

Special guests at this year's festival include Diego Luna, Tim Heidecker, Hannah Einbinder, Gillian Anderson, Jane Schoenbrun ...

ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology ...

Operator: Good afternoon, and welcome to Relmada Therapeutics First Quarter Earnings Conference Call. At this time, all ...

Q1 2026 earnings call recap: revenue fell to $2.8M but guidance holds at $16–$18M amid NIH pressure, competition & IP suit—read now.

Plaintiffs who expand their class definition beyond the complaint risk losing both certification and their class ...

The Ole Miss softball program is set to open up play in the 2026 NCAA Tournament, competing in the Lubbock Regional, hosted ...

MIND C.T.I. LTD. – (NasdaqGM: MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for service providers, unified communications (UC) ...